Treatment-related adverse events in 127 patients treated with pembrolizumab
| Adverse event | Any grade n (%) | Grade 3–4 n (%) |
| Fatigue | 25 (20) | |
| Rash, maculopapular | 17 (13) | |
| Hypothyroidism | 14 (11) | |
| Anorexia | 11 (9) | |
| Aspartate aminotransferase increased | 9 (7) | 1 (1) |
| Alanine aminotransferase increased | 8 (6) | 2 (2) |
| Anemia | 8 (6) | 4 (3) |
| Arthralgia | 6 (5) | |
| Alkaline phosphatase increased | 5 (4) | 1 (1) |
| Hyperthyroidism | 4 (3) | |
| Nausea | 4 (3) | |
| Pneumonitis | 4 (3) | 3 (2) |
| Diarrhea | 3 (2) | 1 (1) |
| Pruritus | 3 (2) | |
| Dyspnea | 2 (2) | |
| Edema, limbs | 2 (2) | |
| Hyperglycemia | 2 (2) | 1 (1) |
| Myalgia | 2 (2) | |
| Peripheral sensory neuropathy | 2 (2) | |
| Skin and subcutaneous tissue disorders—Other, specify* | 2 (2) | |
| Skin infection | 2 (2) | |
| Arthritis | 1 (1) | 1 (1) |
| Blood bilirubin increased | 1 (1) | |
| Colitis | 1 (1) | 1 (1) |
| Creatinine increased | 1 (1) | |
| Dry skin | 1 (1) | |
| Dysgeusia | 1 (1) | |
| Genital edema | 1 (1) | |
| Hyponatremia | 1 (1) | |
| Thyroiditis | 1 (1) | |
| Mucositis, oral | 1 (1) | |
| Tremor due to subacute progressive cerebellar dysfunction | 1 (1) | 1 (1) |
*Rash other than maculopapular rash